tbuckley/cabot-search huggingface dataset:
Abstract 806: Extracellular matrix metalloprotease inducer (EMMPRIN) and CD44 protein complexes are exclusively formed in basal- and normal-like breast cancer cell lines
Authors: Annemieke M. Timmermans, Hamed Montazeri, Anita M. Trapman-Jansen, John W. Martens, John A. Foekens, Arzu Umar
Journal: Cancer Research (2012)

Abstract Extracellular Matrix Metalloprotease Inducer (EMMPRIN) is a multifunctional glycoprotein that is involved in tumor cell invasion and metastasis, and is a predictor for tamoxifen resistance in breast cancer. EMMPRIN is implicated in development of therapy resistance by forming a functional transporter complex through interaction with CD44 and monocarboxylate transporter 4. Presence of EMMPRIN transporter protein complexes may therefore be a better predictor for therapy resistance and a direct target for drugs. In this study, we aimed to identify EMMPRIN-CD44 protein interactions in a large panel of breast cancer cell lines. EMMPRIN-CD44 protein interaction was investigated in a panel of 41 breast cancer cell lines, which represent the luminal (n=12), ErbB2 (n=13), basal (n=7), and normal-like (n=9) intrinsic subtypes, using in situ Proximity Ligation Assay (isPLA). In addition, protein expression of both EMMPRIN and CD44 in the cell lines was evaluated by immunohistochemistry (IHC). IHC and isPLA read-out was performed by bright field microscopy and 0-1-2-3 scoring was applied to none-weak-moderate-strong staining (IHC) or interaction (isPLA), respectively. Moderate and strong EMMPRIN expression was observed in 50% of luminal, 36% of ErbB2, 86% of basal, and 100% of normal-like cell lines, and moderate to high CD44 expression was detected in 64%, 83%, 86%, and 100% in luminal, ErbB2, basal, and normal-like cell lines, respectively. Interestingly, moderate to strong EMMPRIN-CD44 interaction was exclusively detected in basal (64%) and normal-like (67%) cell lines, whereas luminal and ErbB2 cells lines had no detectible, or only very weak, EMMPRIN-CD44 interaction (≥square = 23.5, P&amp;lt;0.0001). Our results indicate that EMMPRIN-CD44 protein complexes are formed exclusively in basal and normal-like breast cancer cell lines. These breast cancer subtypes are associated with an aggressive phenotype and poor patient survival. We speculate that active EMMPRIN-CD44 transporters are involved in drug resistance, resulting in poor clinical outcome, and will investigate this in more detail in clinical breast cancer specimens. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 806. doi:1538-7445.AM2012-806
Laparoscopic Partial Hepatectomy for Inflammatory Pseudotumor of the Liver
Authors: S. Seki, H. Sakaguchi, R. Oiso, C. Lee, H. Morikawa, H. Hamba, S. Kubo, K. Hirohashi, H. Kinoshita
Journal: Endoscopy (2001)

A 50-year-old man was admitted for further examination of a 10-mm hepatic mass in subsegment 4. He had cirrhosis of the liver as a result of alcohol abuse, and hepatitis virus markers were all negative. Dynamic computed tomography (CT) revealed a 10-mm hypervascular tumor in the early phase (Figure [1]). On angiography, the tumor was hypervascular, and arterial portographic CT showed that the tumor was low density, indicating that it had no portal flow. Based on these findings, preoperatively we considered the tumor to be a hepatocellular carcinoma.
Interleukin (IL)‐4 and to a lesser extent either IL‐13 or interferon‐gamma regulate the production of eotaxin‐2/CCL24 in nasal polyps
Authors: D. Lezcano‐Meza, B. Dávila‐Dávila, A. Vega‐Miranda, M. C. Negrete‐García, L. M. Teran
Journal: Allergy (2003)

Background: Eotaxin‐2/CCL24 is a potent eosinophil attractant that has been implicated in the recruitment of eosinophils in allergic disease. We have investigated whether the cytokines interleukin (IL)‐4, IL‐13, and interferon (IFN)‐gamma regulate eotaxin‐2/CCL24 in nasal polyps. Methods: Nasal polyps were cultured in the presence of the cytokines described above and the concentration of eotaxin‐2/CCL24 was measured in the culture supernatant. Results: IL‐4 was found to be the major stimulus for eotaxin‐2/CCL24 production from nasal polyps followed by IL‐13 and IFN‐gamma. IL‐4 induced eotaxin‐2/CCL24 in a dose‐dependent manner with concentrations as low as 0.1 ng/ml being able to induce eotaxin‐2/CCL24. By immunohistochemistry, eotaxin‐2/CCL24 immunoreactivity was localized to mononuclear cells in the IL‐4 stimulated nasal polyp tissue. Interestingly, nasal turbinates obtained from patients suffering from nonallergic rhinitis (vasomotor rhinitis) were also found to release eotaxin‐2/CCL24 both spontaneously and following cytokine stimulation with IL‐4 and IFN‐gamma being major inducers of this cytokine. Conclusions: All together these findings suggest that Th1 and Th2 cytokines may regulate eotaxin‐2/CCL24 production in nasal polyps and nonallergic rhinits.
Diagnosis of pyruvate kinase deficiency in a transfusion‐dependent patient with severe hemolytic anemia
Authors: Gert Rijksen, Gerda P. M. Schipper‐Kester, Gerard E. J. Staal, Anjo J. P. Veerman
Journal: American Journal of Hematology (1990)

Abstract In a 2‐yr old girl a hemolytic anemia was present since birth requiring multiple blood transfusions. Pyruvate kinase deficiency was suspected on the basis of a marginal enzyme activity, but could not be established due to the presence of massive numbers of donor cells in her peripheral blood. However, by density fractionation we succeeded in the isolation of a small fraction of the patient's own cells, in which a severe pyruvate kinase deficiency could be detected. In contrast hexokinase and glucose‐6‐phosphate dehydrogenase activities were extremely high, which is indicative that a very immature cell population is present in this fraction. In immunofluorescence studies a clear crossreaction was apparent with anti M 2 ‐type pyruvate kinase antibodies, whereas only a faint reaction with anti L‐type could be detected. Despite the presence of a slight amount of L‐type immunoreactive material, the residual activity in the patient's cell fraction could only be attributed to M 2 ‐type pyruvate kinase as was shown by cellulose acetate electrophoresis.
MYOCARDIAL PERFUSION AFTER INTRACORONARY INFUSION OF MONONUCLEAR CELLS OF BONE MARROW OR PERIPHERAL BLOOD AFTER ACUTE MYOCARDIAL INFARCTION
Authors: Farshid Afsharzada, Robin Nijveldt, Alexander Hirsch, Pieter A van der Vleuten, Aernout M. Beek, Jan G.P. Tijssen, Jan J. Piek, Felix Zijlstra, Albert C. van Rossum
Journal: Journal of the American College of Cardiology (2010)
Abstract 2363: The Usefulness of Serum Hepcidin Measurement in Chronic Heart Failure
Authors: Mika Matsumoto, Takeshi Tsujino, Masaaki Lee-Kawabata, Yoshiro Naito, Akira Ezumi, Shinji Nakao, Akiko Goda, Chikako Yoshida, Kunihiro Akahori, Tsuyoshi Sakoda, Mitsumasa Ohyanagi, Naohisa Tomosugi, Tohru Masuyama
Journal: Circulation (2008)

Objectives: Anemia is associated with poor prognosis in patients with chronic heart failure (CHF). Some previous and ongoing trials try to evaluate the effects of iron supplementation to CHF patients with anemia. Hepcidin is a peptide synthesized mainly in the liver, and its active form hepcidin-25 internalizes the iron exporter ferroportin to suppress iron absorption in the duodenum and iron transport in the reticuculoendothelial cells. Hepcidin is down-regulated by hypoxia, anemia, and erythropoietin (EPO), and up-regulated in chronic inflammation. Subjects are judged to need iron supplementation when both serum hepcidin-25 and ferritin concentration are relatively low (hepcidin-25   Methods: We studied 60 CHF patients who were admitted to our hospital with acute decompensation. There were 26 females, ranging in age from 28 to 92 years (mean 70). They were not administered with EPO and/or iron for treatment of anemia. Hemoglobin (Hb), serum hepcidin-25 (measured by LC-MS/MS), EPO, and ferritin concentration were measured on admission and at discharge. A group of 20 patients without HF were recruited as the control group.  Results: On admission, serum concentration of hepcidin-25 was lower in CHF patients than in controls (10.8 ± 1.7 vs. 17.2 ± 2.6 ng/ml). After treatment, serum hepcidin-25 concentration increased (17.7 ± 2.2 vs. 10.8 ± 1.7 ng/ml), Hb increased (12.5 ± 0.3 vs. 12.2 ± 0.3 g/dl), and EPO decreased (29 ± 4 vs. 73 ± 9 mU/ml) in HF patients. Hepcidin-25 correlated negatively with EPO and positively with ferritin and Hb on admission and at discharge. Among HF patients with anemia (Hb  Conclusions: More than half of CHF patients with anemia were under latent iron deficiency. Hypoxia induced by HF may increase EPO, stimulate erythropoiesis, increase iron requirement, and decrease serum hepcidin concentration. Iron supplementation may be beneficial in such patients.
Management of Hyperlipidemias
Authors: Barbara F. Murphy
Journal: JAMA (1974)

The treatment of hyperlipidemia is desirable, especially in patients with a family history of premature ischemic heart disease, but only after the specific type of hyperlipoproteinemia has been determined. Secondary causes of hyperlipoproteinemia should be sought and eliminated. Dietary regulation remains the primary therapeutic approach; adjunctive chemotherapy is indicated only when dietary control is unsuccessful. Several drugs will reduce lipid levels, but the long-term effects of these drugs are unknown. (<i>JAMA</i>230:1683-1691, 1974)
604 Serum lipoprotein levels during treatment of chronic hepatitis C with Peg-interferon-alpha-2a & ribavirin — a differential effect on genotype 3 patients
Authors: Y. Rotman, Z. Levi, R. Hazazi, M. Cohen, O. Cohen-Ezra, V. Manhaim, M. Braun, Z. Ben-Ari, R. Tur-Kaspa
Journal: Journal of Hepatology (2006)
Scientific and Ethical Issues in Equivalence Trials
Authors: Benjamin Djulbegovic
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
665 PML NUCLEAR BODY COMPONENT SP140 IS A NOVEL AUTOANTIGEN IN PRIMARY BILIARY CIRRHOSIS
Authors: A. Granito, W. Yang, L. Muratori, P. Muratori, M.J. Lim, G. Pappas, S. Ferri, C. Quarneti, D. Bloch, F.B. Bianchi
Journal: Journal of Hepatology (2009)
Abstract 978: Secondhand tobacco smoke in bars and restaurants in Guatemala: Before and after indoor smoking ban evaluation
Authors: Mariel Arvizu, Juan Carlos Hernandez, Joaquin Barnoya, Ana Navas-Acien
Journal: Cancer Research (2010)

Abstract Since February 2009 Guatemala has implemented a smoke-free law that includes bars and restaurants. In this study, we sought to assess air nicotine levels in bars and restaurants 6 months after the implementation of the law (post-law) and to compare them with levels found in 2007 (pre-law). Exposure was estimated by passive sampling of vapor-phase nicotine using a filter badge. Filters were placed for 7 working days in 10 bars and 11 restaurants randomly selected in Guatemala City. In total, 50 monitors were placed (for quality control, 10% were duplicate and blank). Filters were checked once to verify the correct placement, count the number of persons and smokers if there were any. Nicotine was measured by gas-chromatography and the time weighted average concentration in µg/m3 was estimated. Median (interquantile range, IQR) air nicotine levels are presented and compared using Mann-Whitney rank test. In addition, 32 employees answered a survey about air quality and opinions about secondhand smoke. The survey results were also compared with pre-law survey results using a chi-square statistic. Before the law, detectable levels of nicotine were found in all bars and restaurants. Median nicotine levels were 4.57 (IQR 1.71-6.44) μg/m3 in bars and 0.58 (IQR 0.43-0.7) μg/m3 in restaurants. After the law, nicotine was detected in all bars and most (76%) restaurants. Median nicotine levels were 0.59 (IQR 0.17-0.80) μg/m3 in bars and 0.06 (IQR 0.01-0.09) μg/m3 in restaurants. These levels were significantly lower compared to those found before the law (p=0.003 and p=0.05; respectively). The nicotine reduction was similar in bars (87%) and restaurants (89%). Employees’ support for a smoke-free workplace rose significantly after the law was implemented (from 32% to 81%, p&amp;lt;0.001). In conclusion, six months after the law went into effect, nicotine levels were significantly decreased in bars and restaurants and workers support for the law was high. Given that no other tobacco control law has been implemented in Guatemala, our results can be attributed to the smoke-free law. However, in order to be effective in reducing lung cancer incidence a smoke-free law should be strictly enforced. Our data should prove useful to exert pressure upon the Guatemalan government to more strictly enforce the law. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 978.
Potential Cancer Therapy With the Fragile Histidine Triad Gene
Authors: Hideshi Ishii, Kristoffel R. Dumon, Andrea Vecchione, Louise Y. Y. Fong, Raffaele Baffa, Kay Huebner, Carlo M. Croce
Journal: JAMA (2001)

The fragile histidine triad gene (FHIT) encompasses a human common fragile site, FRA3B, that is susceptible to environmental carcinogens. Deletion and inactivation of FHIT have been seen in a number of human premalignant and malignant lesions.To review and evaluate preclinical studies of cancer therapy using the FHIT tumor suppressor gene and related studies involving Fhit protein expression.A MEDLINE search of articles published from 1996 to June 2001 was performed; article reference lists were used to retrieve additional relevant articles.Immunohistochemical studies of primary tumors or relevant lesions were selected to evaluate Fhit expression in premalignant or malignant stages. Preclinical studies on antitumorigenic or therapeutic introduction of FHIT were reviewed for the effects of exogenous Fhit expression. For the immunohistochemical analyses, 26 studies were included that analyzed at least 15 cases of a single type of tumor. For precancerous lesions, 9 studies were included that analyzed at least 4 cases. For studies of FHIT introduction, 9 published studies were included.Using primary data from each of the studies, we assessed the rationale and potential contribution of FHIT cancer therapy. Data was independently abstracted by 2 authors and study quality was assessed by 2 other authors.Overall, 60% (1162/1948 cases) of primary tumors showed absent or markedly reduced Fhit protein expression in cancer cells. Studies of preneoplastic lesions or early-stage cancer showed absence or marked reduction of Fhit protein expression in 0% to 93% of samples (overall, 31% [127/408 cases]). Preclinical studies using 26 cancer-derived cell lines from human lung, head and neck, esophageal, gastric, cervical, pancreatic, and kidney cancers, showed that reintroduction of FHIT resulted in inhibition of in vitro tumor cell growth or of in vivo tumorigenicity in 17 (57%) of 30 cell line experiments. Model systems for human preventive cancer therapy suggested that oral introduction of viral vector-mediated FHIT into Fhit-deficient mice may prevent carcinogen-induced tumor development in some cases.These findings show that FHIT gene therapy may potentially be clinically useful for treatment of cancer and also prevention of carcinogen-induced tumor development, suggesting a rationale for further research involving FHIT introduction.
NCI Changes Its Stance on Mammography
Authors: Charles Marwick
Journal: JAMA (1994)

THE NATIONAL Cancer Institute (NCI) has changed its policy regarding routine mammographic screening for breast cancer in asymptomatic women under the age of 50 years. The institute has issued a statement alerting women in this age group to the fact that until now, randomized clinical trials of routine screening mammography "have not shown a statistically signficant reduction in mortality in women under the age of 50." The NCI shies away from referring to the statement it issued on December 3, 1993, as a "guideline," but the new position effectively reverses its own "working guidelines," which date back to 1987. These recommended routine screening of women under 40 years of age as well as those over 50. Among women over 50 years of age, screening is still worth doing, according to these authorities. In this older group, "there is a general consensus among experts that routine screening every 1 to 2
Characterisation and localisation of a 67 kDa calcium binding protein (p67) isolated from bovine hearts
Authors: L. Wang, H. Iida, Y. Shibata
Journal: Cardiovascular Research (1993)

Journal Article Characterisation and localisation of a 67 kDa calcium binding protein (p67) isolated from bovine hearts Get access Luming Wang, Luming Wang Department of Anatomy, Faculty of Medicine, Kyushu University, Fukuoka 812, Japan: L Wang, H Iida, Y Shibata. Correspondence to Dr Iida. Search for other works by this author on: Oxford Academic PubMed Google Scholar Hiroshi Iida, Hiroshi Iida Department of Anatomy, Faculty of Medicine, Kyushu University, Fukuoka 812, Japan: L Wang, H Iida, Y Shibata. Search for other works by this author on: Oxford Academic PubMed Google Scholar Yosaburo Shibata Yosaburo Shibata Department of Anatomy, Faculty of Medicine, Kyushu University, Fukuoka 812, Japan: L Wang, H Iida, Y Shibata. Search for other works by this author on: Oxford Academic PubMed Google Scholar Cardiovascular Research, Volume 27, Issue 10, October 1993, Pages 1855–1862, https://doi.org/10.1093/cvr/27.10.1855 Published: 01 October 1993 Article history Received: 19 October 1992 Accepted: 09 December 1992 Published: 01 October 1993
The Justice Department's Case against the Tobacco Companies
Authors: Michael C. Fiore, Paula A. Keller, Timothy B. Baker
Journal: New England Journal of Medicine (2005)

The case brought by the Department of Justice against the tobacco industry — the largest civil litigation in U.S. history — has become mired in controversy. Projections suggest that about 23 million Americans, or one of every two current smokers, will die prematurely because of a disease caused by tobacco use. The lawsuit called for actions to remedy harms that have resulted directly from misconduct on the part of the tobacco industry. Unfortunately, Justice Department attorneys shifted gears at the 11th hour, drastically reducing the remedies proposed by their own expert witness, and reports surfaced that government witnesses were pressured . . .
Bone Dystrophy Associated with Muscular Dystrophy
Authors: D. W. Ashby, G. E. O. Williams, O. E. Smith
Journal: BMJ (1951)

MEIA ORA -that is, the presence of a ninhydrin reactor (Fig. 1, symbc$ 18) not reported by Dent (1948) as occurring in human urine.Work on the isolation and identifi- cation of this compound will form the basis of a separate communication.In conclusion it can be said that re- section of 16% of the liver produced no specific change in amino-acid metabolism.Urinary Urobilih(ogen) Before resection the excretion was within normal limits.During the eight days immediately following
Comparison Between Two Maintenance Feeding Regimens After Successful Cow's Milk Oral Desensitization
Authors: Giovanni B. Pajno, Lucia Caminiti, Giuseppina Salzano, Giuseppe Crisafulli, Tommaso Aversa, Francesca Maria Messina, Malgorzata Wasniewska, Giovanni Passalacqua
Journal: Journal of Allergy and Clinical Immunology (2013)
195. Tat Peptide Conjugates of Low Molecular Weight Polyethylenimine as Effective Non-Viral Gene Delivery Vectors
Authors: Shu Wang
Journal: Molecular Therapy (2006)

Tat peptide derived from the arginine-rich basic domain of the HIV transactivator of transcription are capable of mediating intracellular delivery of various types of drugs, including large biomolecules and nanoparticulate drug carriers. For gene delivery, several recent publications reported that Tat peptide-mediated transfection in cultured cells is strongly dependent on the addition into the culture medium of chloroquine, a weak base that inhibits fusion of the endosome with the lysosome by buffering the lysosome interior. While effective in vitro, the chloroquine co-treatment is not a feasible approach for in vivo gene delivery application. We reasoned that protonable amines in polyethylenimines (PEIs) could be used to replace chloroquine. We developed a solid-phase chemical synthetic method to synthesize a peptide-polymer hybrid. PEI600 was conjugated to the last glycine residue of Tat peptide on a resin support right after solid phase peptide synthesis when the side chains of other peptide residues were still protected. The PEI600-Tat conjugates could bind to and fully condense plasmid DNA, as demonstrated in a DNA retardation assay and particle size measurement. The biophysical parameters of the PEI600-Tat/DNA complexes were similar to those of DNA complexes compacted with PEI 25kDa, the gold standard for nonviral gene carriers. Transfection experiments demonstrates that the use of PEI600-Tat conjugates was more effective than the use of the two compounds without chemical conjugation and that the P600-Tat conjugate and PEI 25kDa provided similar levels of transfection efficiency in cultured cells. Attractively, the newly developed conjugates maintain the desirable property of low cytotoxicity displayed by lower molecular weight PEI polymers and Tat peptides. Thus, a new polymer-peptide hybrid was prepared using a versatile methodology that couples synthetic polymers directly to resin-supported peptides. The developed hybrid biomaterial takes advantage of the unique features associated with the two original cationic materials and functions as a novel gene delivery vector with good biocompatibility.
Pseudomonas aeruginosa II lectin stops human ciliary beating: therapeutic implications of fucose.
Authors: E C Adam, B S Mitchell, D U Schumacher, G Grant, U Schumacher
Journal: American Journal of Respiratory and Critical Care Medicine (1997)

Respiratory tract infection by Pseudomomas aeruginosa may be life-threatening for intensive care patients and patients with cystic fibrosis (CF). The colonization of airways can be facilitated by bacterial lectins (carbohydrate-binding proteins) that attach bacteria to the glycoconjugates of the mucosa. We show in this paper that the fucose-specific lectin P. aeruginosa agglutinin II (PAII) produced by these bacteria can, in addition to facilitating bacterial adhesion, arrest ciliary beating in human airways in vitro. This inhibitory effect of the lectin can be abolished by preincubating PAII with its specific sugar, fucose. Furthermore, ciliary beating is completely restored by addition of fucose 2 h after administration of PAII to cell cultures. Therefore, adding a simple monosaccharide to nebulizers may improve the management of P. aeruginosa infection by abrogating the effect of PAII on ciliary beating, thus restoring part of the nonspecific pulmonary defense mechanisms of the airways.